Skip to main content

Myeloperoxidase aggravates thoracic aortic aneurysm formation in Marfan disease.

Cardiovascular research

Authors: Dennis Mehrkens, Johannes Dohr, Felix Sebastian Nettersheim, Felix Ballmann, Jil Bastigkeit, Alexander Brückner, Simon Geissen, Lauren De Vore, Cedric Fitsch, Chris Diekmann, Andrea de la Fuente-Alonso, Patrik Schelemei, Felix Ruben Picard, Malte Kochen, Per Arkenberg, Anna Rappenecker, Maysam Ahdab, Harshal Nemade, Suchitra Narayan, Simon Braumann, Wiebke Kreuzberg, Alexander Hof, Henning Guthoff, Benedicta Quaye Mensah, Sebastian Lechner, Andrea Guala, Artur Evangelista, Gisela Teixido-Tura, J Francisco Nistal, Miguel R Campanero, Harald Kaemmerer, Zsuzsanna Wolf, Stefan Holdenrieder, Maarten Groenink, Mitzi van Andel, Arnout Mieremet, Susanne Pfeiler, Norbert Gerdes, Ulrich Flögel, Laura-Maria Zimmermann, Gerhard Sengle, Marie-Lisa Eich, Birgid Schömig-Markiefka, Matti Adam, Bernd K Fleischmann, Daniela Wenzel, Juan Miguel Redondo, Vivian de Waard, Anna Klinke, Stephan Baldus, Martin Mollenhauer, Holger Winkels

AIMS: Patients suffering from Marfan syndrome (MFS), the most prevalent inherited connective tissue disorder, face premature mortality due to dissection and rupture of thoracic aortic aneurysms. Here, we questioned whether myeloperoxidase (MPO), a leucocyte-derived enzyme with high affinity to the vessel wall, contributes to aortic remodelling in MFS.

METHODS AND RESULTS: Plasma MPO levels were evaluated in MFS patients and healthy controls. Thoracic aortic aneurysm formation was determined in heterozygous transgenic Fbn1C1041G/+ (MFS) mice, MPO-deficient MFS mice (MFSxMpo-/-), and MFS mice treated with an MPO inhibitor by ultrasound and histology.MFS patients exhibited increased circulating MPO levels and marked aortic MPO deposition. In MFS mice, MPO-deficiency reduced aortic elastin fragmentation and aneurysm formation. RNA sequencing revealed an inflammatory gene program in aortic endothelial cells isolated from MFS mice in comparison to WT and MFSxMpo-/- mice. This was accompanied by enhanced endothelial expression of the leucocyte adhesion molecule ICAM-1, increased leucocyte adhesion, and, consequently, leucocyte infiltration in MFS aortae. Moreover, MPO directly contributed to adverse extracellular matrix remodelling through overproduction of reactive oxygen species and subsequent vascular protein modifications leading to enhanced matrix metalloproteinase 2/9 activity. Lastly, treatment of MFS mice with the orally available MPO inhibitor AZM198 attenuated TAA formation.

CONCLUSION: MPO is increased in MFS and contributes to thoracic aortic dilatation by inducing inflammatory endothelial activation, oxidative stress, and adverse extracellular matrix remodelling. Pharmacological and genetic inhibition of MPO reduced MFS-related aortic dilation in mice, highlighting MPO as a promising therapeutic target in MFS.

© The Author(s) 2025. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

PMID: 41403006

Participating cluster members